3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Thrombocytopenia
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neutropenia
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphopenia
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Graft vs Host Disease
1
Cytopenia
1
Anemia
1
Interventions
Azacitidine
142
Cytarabine
109
venetoclax
94
fludarabine
35
Daunorubicin
34
Decitabine
32
Idarubicin
26
gilteritinib
24
Cyclophosphamide
21
quizartinib
15
midostaurin
15
Mitoxantrone
14
Etoposide
14
Granulocyte Colony-Stimulating Factor
12
Gemtuzumab
11
CPX-351
11
decitabine and cedazuridine drug combination
10
Drug Therapy
10
cc-486
9
Filgrastim
9
Clofarabine
9
ivosidenib
8
Injections
8
Dexamethasone
8
pevonedistat
7
fludarabine phosphate
7
AP 1903 reagent
7
posaconazole
6
magrolimab
6
glasdegib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Acute
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled